Oyster Therapeutics raises $60m to develop next generation Alzheimer's treatments

London based biotechnology company Oyster Therapeutics has raised $60m in Series A funding led by 4BIO Capital, with participation from Eli Lilly and other investors. The funding will support the development of treatments targeting tau proteins associated with Alzheimer's disease and other neurological conditions. HPC could introduce pharmaceutical manufacturers, clinical research organisations, laboratory equipment suppliers and specialist healthcare investors to support the company's development and expansion.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.